申请人:Astellas Pharma Inc.
公开号:EP3153511A1
公开(公告)日:2017-04-12
To provide a compound useful as an active ingredient of a pharmacological composition for the treatment of urinary storage symptoms, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors perfected the present invention after discovering that thiazole derivatives substituted at position 2 by pyrazinylcarbonylamino are exceptional muscarinic M3 receptor positive allosteric modulators and can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors. The 2-acylaminothiazole derivatives or salts thereof of the present invention can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors, e.g., underactive bladder and the like.
提供一种化合物,作为治疗储尿症状、排尿困难、下尿路疾病等的药理组合物的有效成分。[解决方案]本发明者发现在第 2 位被吡嗪基羰基氨基取代的噻唑衍生物是一种特殊的毒蕈碱 M3 受体正异位调节剂,可望作为预防或治疗涉及毒蕈碱 M3 受体介导的膀胱收缩的膀胱和尿路疾病的药物,从而完善了本发明。本发明的2-乙酰氨基噻唑衍生物或其盐可望用作预防或治疗涉及毒蕈碱M3受体介导的膀胱收缩的膀胱和尿路疾病的药物,例如膀胱功能不全等。